Enhancing transduction efficiency of adeno-associated virus 9 by cell line engineering: implication for gene therapy potency assay
Tóm tắt
Adeno-associated virus (AAV)-mediated gene therapy holds significant promises to treat or potentially cure various human diseases. Although AAV holds promise for their significant therapeutic potential, batch-to-batch differences can exist from manufacturing; and therefore, a potency assay is required for clinical development of AAV. Among different serotypes, due to its ability to cross blood–brain barrier and wide-spread transduction capability in vivo upon systemic administration, AAV9 has been widely utilized for the development of treatment of neurological disorders. However, as AAV9 is known to show poor transduction in vitro, establishing a robust in vitro potency assay have been difficult. To this end, we engineered HEK293T and Schwann-like cell lines to express previously identified common AAV receptor, AAVR or endogenous host factor involved in AAV endosomal escapes, GPR108 that can increase infectivity of AAVs in an attempt to increase transduction capability of AAV9. We found that AAVR overexpressed Schwann-like cell line showed significant increase in AAV9 transduction; whereas, GPR108 overexpression showed no effect on AAV9 transduction. On the other hand, GPR108 engineered HEK293T showed increase in AAV9 transduction; whereas, AAVR overexpressed HEK293T cell line showed modest increase in AAV9 transduction. Gene expression analysis showed that AAVR is highly expressed in HEK293T compared to Schwann-like cell line; whereas, GPR108 is highly expressed in Schwann-like cell line when compared to HEK293T. These results indicate that different cell lines may require different gene engineering to increase AAV9 infectivity and analysis of endogenous expression of AAV entry factors for cell line to be engineered can improve efficiency of cell line engineering for AAV transduction.
Từ khóa
Tài liệu tham khảo
Bartlett JS, Wilcher R, Samulski RJ (2000) Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J Virol 74:2777–2785. https://doi.org/10.1128/jvi.74.6.2777-2785.2000
Zincarelli C, Soltys S, Rengo G et al (2008) Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 16:1073–1080. https://doi.org/10.1038/mt.2008.76
Pillay S, Meyer NL, Puschnik AS et al (2016) An essential receptor for adeno-associated virus infection. Nature 530:108–112. https://doi.org/10.1038/nature16465
Dudek AM, Zabaleta N, Zinn E et al (2020) GPR108 is a highly conserved AAV entry factor. Mol Ther 28:367–381. https://doi.org/10.1016/j.ymthe.2019.11.005
Shen S, Bryant KD, Sun J et al (2012) Glycan binding avidity determines the systemic fate of adeno-associated virus type 9. J Virol 86:10408–10417. https://doi.org/10.1128/JVI.01155-12
Kuzmin DA, Shutova MV, Johnston NR et al (2021) The clinical landscape for AAV gene therapies. Nat Rev Drug Discov 20:173–174. https://doi.org/10.1038/d41573-021-00017-7
Bell CL, Vandenberghe LH, Bell P et al (2011) The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice. J Clin Invest 121:2427–2435. https://doi.org/10.1172/JCI57367
Lee JS, Lee JY, Song DW et al (2020) Targeted PMP22 TATA-box editing by CRISPR/Cas9 reduces demyelinating neuropathy of Charcot-Marie-Tooth disease type 1A in mice. Nucleic Acids Res 48:130–140. https://doi.org/10.1093/nar/gkz1070
Au HKE, Isalan M, Mielcarek M (2022) Gene therapy advances: a meta-analysis of AAV usage in clinical settings. Front Med 8:809118. https://doi.org/10.3389/fmed.2021.809118
Shen S, Bryant KD, Brown SM et al (2011) Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J Biol Chem 286:13532–13540. https://doi.org/10.1074/jbc.M110.210922
Banning A, Zakrzewicz A, Chen X et al (2021) Knockout of the CMP-sialic acid transporter SLC35A1 in human cell lines increases transduction efficiency of adeno-associated virus 9: implications for gene therapy potency assays. Cells 10:1259. https://doi.org/10.3390/cells10051259